DTU Logo
About the DTU | News | Staff | Alumni | Contact/Find us | Job opportunities

More effective glycaemic control seen with rosiglitazone is explained by effects on both β-cell function and insulin sensitivity

22-Mar-2011

The ADOPT study (A Diabetes Outcomes Prevention Trial) showed that treatment with rosiglitazone alone provided somewhat more effective glycaemic control than metformin or glyburide alone, in patients with recently diagnosed type 2 diabetes. In a paper published recently in Diabetes, we examined changes in β-cell function and insulin sensitivity among the three treatments in ADOPT.

We found that more favourable changes were seen in both β-cell function and insulin sensitivity in patients allocated rosiglitazone, compared with those allocated metformin or glyburide, explaining the more effective glycaemic control observed with rosiglitazone.


[Link]